2 of 3 medicines approved as orphan drug was ‘anticancer drug’ this year
This year, 2 of 3 products approved as orphan drug were reportedly an anticancer drug.
Also, 2 products were generated by Korean pharmaceutical companies as an orphan drug by acquiring the preferential sale product approval with avoiding patents.
According to the Ministry of Food and Drug Saf...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
